Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma

Sponsor
iOMEDICO AG
Study ID
NCT05954780
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Selinexor — DRUG
    Selinexor/bortezomib/dexamethasone according to Nexpovio® SmPC

Study Details

The non-interventional study SEATTLE aims to answer open scientific questions regarding QoL and tolerability/safety and AE management of selinexor as well as effectiveness and dosing in clinical routine. Thus, SEATTLE will provide real-world evidence complementary to pivotal studies.

Key Dates

Start date
Jun 28, 2023
Status verified
Jan 2026
Primary completion
Oct 30, 2026
Completion
Oct 30, 2026

Study Design

Enrollment
75 participants (actual)

Arms

  • Arm: second line and later lines therapy
    Patients enrolled for second line or later lines therapy with selinexor in combination with bortezomib and dexamethasone.

Primary Outcome Measure

Change from baseline of EORTC global health scale [ Time Frame: Baseline, up to 40 months ]

Related Studies